Advanced Pipeline

Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 Approved
Autologous BCDA-01 : CardiAMP Cell Therapy

Indication : Ischemic Heart Failure (NCT# 02438306)

Autologous BCDA-02 : CardiAMP Cell Therapy

Indication : Chronic Myocardial Ischemia (NCT# 03455725)

NK1R+ Allogenic BCDA-03: CardiALLO Cell Therapy

Indication : Ischemic Heart Failure

NK1R+ Allogenic BCDA-04: CardiALLO Cell Therapy

Indication: COVID-19 ARDS

Helix Partner: CellProthera

Indication: Acute Infarction (EXCELLENT NCT# 02669810)

Funded by Partner

Helix Partner: Centro Cardiologico Monzino

Indication: Heart Failure (RECARDIO NCT# 02059681)

Funded by Partner

BioCardia is developing two comprehensive biotherapeutic candidates for cardiac regenerative medicine.

  • CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)
  • NK1R+ MSC allogenic culture expanded mesenchymal stem cells derived from bone marrow  (donor-derived)  

Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy.  NK1R+ MSCs utilize younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy. 

The NK1R+ MSC platform is also being advanced clinically for the pulmonary indication of acute respiratory distress.

News


Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.